Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.

2.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184.

3.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group.

J Antimicrob Chemother. 2017 Jan;72(1):246-253. Epub 2016 Sep 13.

PMID:
27629070
4.

Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.

Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sanchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I; VACH Study Group.

HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1.

PMID:
27476742
5.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Sep;15(9):998.

PMID:
26062881
6.

Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.

PLoS Med. 2013;10(9):e1001510. doi: 10.1371/journal.pmed.1001510. Epub 2013 Sep 3.

7.

Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.

Macías J, Márquez M, Téllez F, Merino D, Jiménez-Aguilar P, López-Cortés LF, Ortega E, von Wichmann MA, Rivero A, Mancebo M, Santos J, Pérez-Pérez M, Suárez-Lozano I, Romero-Palacios A, Torres-Cornejo A, Pineda JA.

Clin Infect Dis. 2013 Nov;57(10):1401-8. doi: 10.1093/cid/cit537. Epub 2013 Aug 14.

PMID:
23946224
8.

Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.

Pérez-Molina JA, Mora Rillo M, Suárez-Lozano I, Casado-Osorio JL, Teira Cobo R, Rivas González P, Pedrol Clotet E, Hernando-Jerez A, Domingo P, Barquilla Díaz E, Esteban H, González-García J; Gesida 5808 Study Group.

HIV Clin Trials. 2012 May-Jun;13(3):131-41. doi: 10.1310/hct1303-131.

PMID:
22592093
9.

[GESIDA quality care indicators for the care of persons infected by HIV/AIDS].

von Wichmann MÁ, Locutura J, Blanco JR, Riera M, Suárez-Lozano I, Saura RM, Vallejo P; Grupo de Estudio del Sida (GESIDA).

Enferm Infecc Microbiol Clin. 2010 Nov;28 Suppl 5:6-88. doi: 10.1016/S0213-005X(10)70048-3. Spanish.

PMID:
22008585
10.

Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.

Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, Muñoz A, Domingo P, Ribera E, Cosín J, Viciana P, Lozano F, Terrón A, Vergara A, Teira R, Muñoz-Sánchez J, Roca B, Sánchez T, López-Aldeguer J, Deig E, Vidal F, Pedrol E, Castaño-Carracedo M, Puig T, Garrido M, Suárez-Lozano I.

BMC Womens Health. 2011 Aug 4;11:36. doi: 10.1186/1472-6874-11-36.

11.

Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.

Pérez-Molina JA, Suárez-Lozano I, Del Arco A, Teira R, Bachiller P, Pedrol E, Martínez-Alfaro E, Domingo P, Mariño A, Ribera E, Antela A, de Otero J, Navarro V, González-García J; Gesida 5808 Study Group.

HIV Clin Trials. 2011 Jan-Feb;12(1):1-8. doi: 10.1310/hct1201-1.

PMID:
21388936
12.

Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study.

Pérez Molina JA, Rillo MM, Suárez-Lozano I, Casado Osorio JL, Cobo RT, González PR, Clotet EP, Jerez AH, Pedrol PD, Royuela A, Díaz EB, Esteban H, González-García J.

Curr HIV Res. 2010 Oct;8(7):521-30.

PMID:
21073441
13.

[Epidemiology of HIV infection through cohort studies: a look on the past in order to influence on the future].

Suárez-Lozano I.

Med Clin (Barc). 2010 May 8;134(13):587-8. doi: 10.1016/j.medcli.2010.01.005. Epub 2010 Mar 6. Spanish. No abstract available.

PMID:
20207372
14.

Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort.

Teira R, Suárez-Lozano I, Lozano F, Viciana P, Domingo P, Galindo P, Geijo P, Terrón A, González J, Cosín J, Ribera E, Roca B, García-Alcalde ML, Sánchez T, Muñoz-Sánchez A, Vergara A, López-Aldeguer J, Pedrol E, Vidal F, Garrido M, Santamaría JM.

Enferm Infecc Microbiol Clin. 2010 May;28(5):266-72. doi: 10.1016/j.eimc.2009.04.018. Epub 2010 Feb 2.

PMID:
20129716
15.

The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients.

Suarez-Lozano I, Viciana P, Lacalle JR, Teira R, Lozano F, Lopez-Aldeguer J, Pedrol E, Domingo P, Cosin J, Roca B, Geijo P, Fuente B, Vergara A, Ribera E, Galindo MJ, Zapata A, Sanchez T, Vidal F, Munoz-Sanz A, Munoz-Sanchez J, Garrido M.

HIV Med. 2009 Oct;10(9):573-9. doi: 10.1111/j.1468-1293.2009.00731.x.

16.

Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.

Domingo P, Suarez-Lozano I, Torres F, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldeguer J, Roca B, Gonzalez J, Lozano F, Garrido M; VACH Cohort Study Group.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):582-7. doi: 10.1097/QAI.0b013e3181adcb01.

PMID:
19512939
17.

Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.

Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group.

J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6.

PMID:
18988678
18.

First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.

Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, García Alcalde ML, Cosín J, Terrón A, Galindo MJ, Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M.

J Antimicrob Chemother. 2008 Jun;61(6):1348-58. doi: 10.1093/jac/dkn121. Epub 2008 Mar 20.

PMID:
18356150
19.

[Assessment of clinical practice in patients with infectious meningitis].

Martín-Aspas A, Suárez-Lozano I, Fajardo Pico JM, Ramírez E, Menchero A, de la Iglesia A.

Enferm Infecc Microbiol Clin. 2007 Apr;25(4):242-6. Spanish.

PMID:
17386218
20.

[Delayed diagnosis of HIV infection in the Spanish VACH cohort [1997-2002]].

Teira Cobo R, Suárez Lozano I, Santamaría Jáuregui JM, Terrón Pernía A, Domingo Pedrol P, González García J, Cosín Ochaita J, Ribera Pascuet E, Sánchez T, Roca Villanueva B, Viciana Fernández P, García Alcalde ML, Geijo Martínez P, Galindo Puerto P, Vergara Campos A, Lozano de León Naranjo F, Muñoz Sánchez A, Tebas P.

Gac Sanit. 2007 Jan-Feb;21(1):66-9. Spanish.

Supplemental Content

Loading ...
Support Center